Thirdly, although pharmacological EZH2 inhibition by DZNep shows broad anti-tumor effect in several cancers, including but not limited to prostate cancer, breast cancer, acute myeloid leukemia, and particular renal cell carcinoma [41–44]. The gene discussed is EZH2; the disease is cancer.